ArticleAmerican journal of translational research2021
Effect of gangliosides combined with mouse NGF on the expression of serum HIF-1α, NSE, and sICAM-1 levels in neonates with HIE.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Aberrant Ganglioside Functions to Underpin Dysregulated Myelination, Insulin Signalling, and Cytokine Expression: Is There a Link and a Room for Therapy?Biomolecules · 2022Review
- Retained Primitive Reflexes and Potential for Intervention in Autistic Spectrum Disorders.Frontiers in neurology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study was intended to evaluate the effects of gangliosides combined with mouse nerve growth factor (NGF) on the expression of serum hypoxia-inducible factor-1α (HIF-1α), neuron-specific enolase (NSE), and soluble intercellular adhesion molecule-1 (sICAM-1) levels in neonates with ischemic-hypoxic encephalopathy (HIE).
methodsOne hundred and thirty neonates with HIE admitted to our hospital from May 2017 to April 2019 were grouped into two groups according to the protocol of a randomized controlled trial, with 65 cases in each group. The control group received ganglioside treatment, while the combined group was treated with ganglioside + NGF for 2 weeks.
resultsThe total effective rate of treatment was higher in the combined group (90.77%) than in the control group (76.92%). The recovery time of sucking, consciousness, muscle tone and primitive reflexes was shorter in the combined group than in the control group, and the incidence of neurological sequelae was lower after 1 year in the combined group (4.62%) than in the control group (15.38%) (
conclusionGangliosides combined with NGF can promote the recovery of muscle tone and reduce neurological sequelae, which may possibly be achieved by repairing damaged neuronal cells, enhancing antioxidant enzyme activity, and promoting the regression of inflammation.
Indexed as
Identifiers
34650728PMC8507039W3206586049What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.